RECRUITING

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

Description

Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.

Conditions

Hereditary Angioedema
Talk to us

Related Conditions:

Hereditary Angioedema

Study Overview

On this page

Study Details

Study overview

Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.

A Prospective, Non-interventional Study in Patients With Type I or II Hereditary Angioedema Using Icatibant for On-demand Treatment of Attacks

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

Condition
Hereditary Angioedema
Intervention / Treatment

-

Contacts and Locations

Fairfax

KalVista Investigative Site, Fairfax, Virginia, United States, 22030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female patients 12 years of age and older
  • 2. Diagnosis of HAE Type I or II, based on US Hereditary Angioedema Association (HAEA) database records and/or verbal confirmation from the patient
  • 3. Currently using icatibant to treat HAE attacks
  • 4. If a patient is receiving long-term prophylactic treatment, they must have been on a stable dose and regimen for at least 3 months prior to the Screening Visit
  • 5. Patient has had at least 2 HAE attacks in the 3 months prior to the Screening Visit, as self-reported verbally by the patient
  • 6. Patient is able to read, understand, and complete the eDiary
  • 7. Patient is willing and able to adhere to all protocol requirements
  • 1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or angioedema associated with urticaria
  • 2. Use of angiotensin-converting enzyme inhibitors
  • 3. Participation in any gene therapy treatment or trial for HAE
  • 4. Participation in any interventional investigational clinical trial within 4 weeks prior to screening
  • 5. Any pregnant or breastfeeding patient

Ages Eligible for Study

12 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

KalVista Pharmaceuticals, Ltd.,

Study Record Dates

2026-04-07